Brind.

Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.

3 reports, 2 independent Updated Aug 19
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Goldman Sachs reiterated a Buy rating on Vertex Pharmaceuticals.1 source
  2. GS and BofM provided financing for RMR deal; Vertex HQ in Boston Seaport District.1 source
  3. Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyGoldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy A
  • Business WireThe RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District NEWTON, Mass., August 07, 2025--(BUSINESS WIRE)--The RMR Group (Nasdaq: RMR) today
  • Insider MonkeyEU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the E